Form 4: Palisade Bio Director Wei Binxian Acquires Stock Options as Compensation

Director Wei Binxian reports acquisition of stock options in Palisade Bio as part of director compensation.

Summary

• On July 11, 2024, Wei Binxian, a director of Palisade Bio, Inc., acquired 2,100 common stock options as partial compensation for services.
• The options were granted under the company's 2021 Equity Incentive Plan.
• The exercise price of the options is $4.49.
• The options vest fully on the one-year anniversary of the grant date and expire on July 11, 2034.
• Following the transaction, Wei Binxian directly owns 2,100 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a standard compensation practice that aligns director interests with shareholders.

Positives

• The acquisition of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Industry Context

Stock option grants to directors are a common practice in the biotech industry to align their interests with the long-term success of the company.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary significantly across the biotech industry depending on the company size, stage of development, and board responsibilities.
• Comparing Palisade Bio's director compensation to peers like Anavex Life Sciences or Cassava Sciences would provide a benchmark, but specific details of their compensation packages would be needed for a thorough comparison.
• Generally, stock option grants are structured to vest over several years to incentivize long-term commitment, which aligns with Palisade Bio's one-year vesting period.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholders by aligning the director's interests with the company's long-term success.
• The director benefits from the compensation package.

Key Dates

Keywords

Palisade Bio, Director Compensation, Stock Options, Form 4, Wei Binxian, Equity Incentive Plan